Loading
A phase 2 trial of HLX43 Dose 1; in colorectal cancer, run by Shanghai Henlius Biotech, now recruiting.
Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer is a phase 2 interventional study registered as NCT07106892 by Shanghai Henlius Biotech, with 60 participants planned, started 2025-09-15 and due to reach its primary completion in 2026-12-30. Interventions recorded: HLX43 Dose 1;, HLX43 Dose 2; and HLX43 Dose 3;.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/